公开(公告)号：US20130115682A1

公开(公告)日：2013-05-09

申请号：US13738235

申请日：2013-01-10

Applicant: SYNTAXIN, LIMITED

Inventor： Keith Alan FOSTER ,  John CHADDOCK ,  Philip MARKS ,  Patrick STANCOMBE ,  Lyndsey DUROSE

IPC: C12N9/50

CPC classification number: C12N9/50 ,  A61K38/00 ,  C07K14/33 ,  C07K2319/06 ,  C07K2319/50 ,  C12N15/62

Abstract: The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on the target cell, which Binding Site is capable of undergoing endocytosis to be incorporated into an endocome within the target cell; a protease cleaving site at which site the fusion protein is cleavable by the protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and the translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the target cell.

Abstract translation: 本发明提供了一种单链多肽融合蛋白，其包含：非细胞毒性蛋白酶或其片段，所述蛋白酶或蛋白酶片段能够切割靶细胞的胞外融合装置的蛋白质; 能够结合靶细胞上的结合位点的靶向物质，所述结合位点能够经历内吞作用以掺入靶细胞内的内皮细胞; 蛋白酶切割位点，其中融合蛋白可被蛋白酶切割，其中蛋白酶切割位点位于非细胞毒性蛋白酶或其片段与靶向部位之间; 以及能够将位于内体内的蛋白酶或蛋白酶片段穿过体内膜并进入靶细胞的胞质溶胶的易位结构域。

公开(公告)号：US20140348828A1

公开(公告)日：2014-11-27

申请号：US14459955

申请日：2014-08-14

Applicant: Syntaxin, Limited

Inventor： Keith Alan FOSTER ,  John Andrew CHADDOCK ,  Conrad Padraig QUINN ,  John Robert PURKISS

IPC: C12N9/52

CPC classification number: C12N9/52 ,  A61K38/1808 ,  A61K38/4886 ,  A61K47/64 ,  C07K16/1282 ,  C07K2319/00 ,  C12Y304/24069

Abstract: The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system and bone cells.

Abstract translation: 本发明涉及通过抑制细胞分泌过程，其药剂及其组合物治疗疾病，以及制备这些药剂和组合物。 本发明特别涉及依赖于内分泌细胞，外分泌细胞，炎症细胞，免疫系统细胞，心血管系统细胞和骨细胞的胞吐活性的疾病的治疗。